塞来昔布联合舒尼替尼对肾癌细胞血管生成和增殖抑制的研究

Research of angiogenesis and inhibition of proliferation in kidney cancer cells by celecoxib combined with sunitinib

目的研究塞来昔布联合舒尼替尼对肾癌细胞血管生成和增殖的抑制作用。方法用肾癌786-0细胞株建立肾癌小鼠模型,成功建模后随机分为A,B,C和D组,每组10只。A组灌胃给予50.0 mg·kg^-1磷酸盐缓冲溶液,qd;B组灌胃给予53.6 mg·kg^-1舒尼替尼,qd;C组灌胃给予50.0 mg·kg^-1塞来昔布,qd;D组灌胃给予50.0 mg·kg^-1塞来昔布,qd+53.6 mg·kg^-1舒尼替尼,qd。4组小鼠均连续给药3周。比较4组小鼠的肿瘤体积,并比较4组肾癌肿瘤组织细胞的血管管腔形成数、管腔形成长度和抑制率。结果干预3周后,A,B,C和D组的肿瘤体积分别为(4.29±0.20),(3.53±0.14),(2.00±0.18)和(1.54±0.07)cm3;A,B,C和D组肾癌肿瘤组织细胞的血管管腔形成数分别为(23.08±4.11),(15.58±3.92),(12.07±3.20)和(8.26±1.24)个,管腔形成长度分别为(7.42±0.47),(6.12±0.51),(4.43±0.45)和(3.85±0.46)mm,培养120 h后的抑制率分别为0,(29.78±1.20)%,(52.41±2.03)%和(63.52±3.99)%。D组的上述指标与A,B,C组比较,差异均有统计学意义(均P<0.05)。结论塞来昔布联合舒尼替尼能抑制肾癌肿瘤组织细胞的血管生成和细胞增殖,诱导细胞凋亡,从而缩小肾癌小鼠的瘤体体积。

Objective To investigate the angiogenesis and inhibition of proliferation in kidney cancer cells by celecoxib combined with sunitinib.Methods The kidney cancer 786-0 cell line was used to establish the model of kidney cancer mice.After successful modeling,the model mice were randomly divided into A,B,C and D groups with 10 mice per group.A group was given 50.0 mg·kg^-1 phosphate buffer solution,qd.B group was given 53.6 mg·kg^-1 sunitinib,qd.C group was given 50.0 mg·kg^-1 celecoxib,qd.D group was given 50.0 mg·kg^-1 celecoxib,qd+53.6 mg·kg^-1 sunitinib,qd.Four groups of mice were given intragastric administration continuously for 3 weeks.The tumor volume of the four groups was compared,and the vascular lumen formation number,lumen formation length and inhibition rates of kidney cancer tissue cells of the four groups were compared.Results After intervention 3 weeks,the tumor volume of A,B,C and D groups were(4.29±0.20),(3.53±0.14),(2.00±0.18)and(1.54±0.07)cm3.The vascular lumen formation number of kidney cancer tumor cells in A,B,C and D groups were(23.08±4.11),(15.58±3.92),(12.07±3.20)and(8.26±1.24),the lumen formation length were(7.42±0.47),(6.12±0.51),(4.43±0.45)and(3.85±0.46)mm,the inhibition rates after culture for 120 h were 0,(29.78±1.20)%,(52.41±2.03)%and(63.52±3.99)%.Compared with A,B and C groups,the above indexes in D group showed statistically significant differences(all P<0.05).Conclusion Celecoxib combined with sunitinib can inhibit angiogenesis and cell proliferation of kidney cancer tumor cells,induce apoptosis,and thus reduce the tumor volume of kidney cancer mice.